Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 6, 2024; 12(4): 820-827
Published online Feb 6, 2024. doi: 10.12998/wjcc.v12.i4.820
Inetetamab combined with tegafur as second-line treatment for human epidermal growth factor receptor-2-positive gastric cancer: A case report
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang, Hai-Yan Liu
Jing-Hao Zhou, Qi-Jun Yi, Ming-Yan Li, Yan Xu, Qi Dong, Cong-Ying Wang, Hai-Yan Liu, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, Tai’an 271000, Shandong Province, China
Author contributions: Liu HY, Zhou JH and Yi QJ conceived, designed and refined the study protocol; Zhou JH contributed to manuscript writing and editing, and data collection; Dong Q and Wang CY contributed to conceptualization and supervision; Xu Y, Li MY and Liu HY revised the manuscript; all authors have read and approved the final manuscript.
Supported by the Science and Technology Innovation Development Project of Tai’an, No. 2021NS160; and the Medical and Health Science and Technology Development Plan of Shandong Province, No. 202102010647.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest related to this manuscript.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Yan Liu, MD, Doctor, Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Tai’an 271000, Shandong Province, China. fylhy1998@163.com
Received: November 6, 2023
Peer-review started: November 6, 2023
First decision: November 16, 2023
Revised: November 22, 2023
Accepted: January 12, 2024
Article in press: January 12, 2024
Published online: February 6, 2024
Processing time: 79 Days and 23.1 Hours
Abstract
BACKGROUND

Human epidermal growth factor receptor-2 (HER-2) plays a vital role in tumor cell proliferation and metastasis. However, the prognosis of HER2-positive gastric cancer is poor. Inetetamab, a novel anti-HER2 targeting drug independently developed in China, exhibits more potent antibody-dependent cell-mediated cytotoxicity than trastuzumab, which is administered as the first-line treatment for HER2-positive gastric cancer in combination with chemotherapy. In this case, the efficacy and safety of inetetamab combined with tegafur was investigated as a second-line treatment for HER2-positive gastric cancer.

CASE SUMMARY

A 52-year-old male patient with HER2-positive gastric cancer presented with abdominal distension, poor appetite, and fatigue two years after receiving six cycles of oxaliplatin combined with tegafur as first-line treatment after surgery, followed by tegafur monotherapy for six months. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received 17 cycles of a combination of inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, and tegafur chemotherapy as the second-line treatment (inetetamab 200 mg on day 1, every 3 wk combined with tegafur twice daily on days 1–14, every 3 wk). Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition and progression-free survival of 17 months. He tolerated the treatment well without exhibiting any grade 3-4 adverse events.

CONCLUSION

Inetetamab combined with chemotherapy for the treatment of metastatic HER2-positive gastric cancer demonstrates significant survival benefits and acceptable safety.

Keywords: Inetetamab; Gastric cancer; Human epidermal growth factor receptor-2 protein; Tegafur; Case report

Core Tip: In this paper, we present a case involving a patient with human epidermal growth factor receptor-2 (HER2)-positive gastric cancer who was received oxaliplatin combined with tegafur as the first-line treatment post surgery. The patient was diagnosed with postoperative recurrence of gastric adenocarcinoma. He received inetetamab, an innovative domestically developed anti-HER2 monoclonal antibody, combined with tegafur chemotherapy as the second-line treatment. Evaluation of the efficacy of the second-line treatment revealed that the patient achieved a stable condition. This is significant because We provided a practical reference case for HER2-positive gastric cancer patients who was received inetetamab that is an innovative domestically developed anti-HER2 monoclonal antibody, which may help to provide survival benefits to some extent.